Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2004 May;75(5):677–685. doi: 10.1136/jnnp.2003.029074

Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease

K Rockwood 1
PMCID: PMC1763555  PMID: 15090558

Abstract

Background: Six cholinesterase inhibitors (ChEIs) have been tested in people with Alzheimer's disease, using methods currently required for regulatory approval. The clinical importance of their treatment effects is controversial.

Objective: To determine whether cholinesterase inhibition produces treatment effects in Alzheimer's disease that are large enough to be clinically detectable.

Methods: Overview analysis of published trials of ChEIs in which the Alzheimer's Disease Assessment Scale—Cognitive Subscale (ADAS-Cog) and a global clinical measure were primary outcomes. Two quantitative summary measures of the treatment effect (Cohen's d and the standardised response mean (SRM)) were calculated and presented as funnel plots. Observed cases analyses and intention to treat (ITT) with the last observation carried forward (LOCF) analyses were compared.

Results: The median Cohen's d effect sizes (ES) using ITT samples with LOCF for the ADAS-Cog were: low dose of a ChEI (n = 8 studies) median ES = 0.15, range = 0.03–0.22; medium dose (n = 13) median ES = 0.23, range = 0.12–0.29; high dose (n = 9) median ES = 0.28, range = 0.01–0.31. In general, the ES were larger when calculated as SRMs (for example, high dose ChEI studies, median SRM = 0.47; range = 0.30–0.63) and highest in the observed cases analyses (for example, high dose median SRM = 0.56, range = 0.35–0.78).

Global clinical scales produced similar estimates of ES (for example, high dose ChEI, ITT/LOCF median Cohen's d = 0.29, range = 0.20–0.47).

Conclusions: ChEIs produce small-moderate effect sizes in clinical trials which are reproducible and demonstrate a dose response. Better descriptions of the patterns of treatment response are needed to guide individual patient decisions about the effectiveness of treatment, but group effects are evident and appear large enough to be clinically detectable.

Full Text

The Full Text of this article is available as a PDF (569.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bahit Maria Cecilia, Cannon Christopher P., Antman Elliott M., Murphy Sabina A., Gibson C. Michael, McCabe Carolyn H., Braunwald Eugene, TIMI 9 Trial and TIMI 9 Registry. Thrombolysis In Myocardial Infarction Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan;145(1):109–117. doi: 10.1067/mhj.2003.43. [DOI] [PubMed] [Google Scholar]
  2. Becker R. E., Colliver J. A., Markwell S. J., Moriearty P. L., Unni L. K., Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord. 1996 Fall;10(3):124–131. doi: 10.1097/00002093-199601030-00003. [DOI] [PubMed] [Google Scholar]
  3. Birks J. S., Melzer D., Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev. 2000;(4):CD001190–CD001190. doi: 10.1002/14651858.CD001190. [DOI] [PubMed] [Google Scholar]
  4. Brodaty Henry, Green Alisa, Koschera Annette. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003 May;51(5):657–664. doi: 10.1034/j.1600-0579.2003.00210.x. [DOI] [PubMed] [Google Scholar]
  5. Burback D., Molnar F. J., St John P., Man-Son-Hing M. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration. Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):534–540. doi: 10.1159/000017201. [DOI] [PubMed] [Google Scholar]
  6. Burns A., Rossor M., Hecker J., Gauthier S., Petit H., Möller H. J., Rogers S. L., Friedhoff L. T. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999 May-Jun;10(3):237–244. doi: 10.1159/000017126. [DOI] [PubMed] [Google Scholar]
  7. Clegg Andrew, Bryant Jackie, Nicholson Tricia, McIntyre Linda, De Broe Sofie, Gerard Karen, Waugh Norman. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. Int J Technol Assess Health Care. 2002 Summer;18(3):497–507. doi: 10.1017/s026646230200034x. [DOI] [PubMed] [Google Scholar]
  8. Cummings J. L., Cyrus P. A., Bieber F., Mas J., Orazem J., Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology. 1998 May;50(5):1214–1221. doi: 10.1212/wnl.50.5.1214. [DOI] [PubMed] [Google Scholar]
  9. Davis K. L., Mohs R. C., Marin D., Purohit D. P., Perl D. P., Lantz M., Austin G., Haroutunian V. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999 Apr 21;281(15):1401–1406. doi: 10.1001/jama.281.15.1401. [DOI] [PubMed] [Google Scholar]
  10. Davis K. L., Thal L. J., Gamzu E. R., Davis C. S., Woolson R. F., Gracon S. I., Drachman D. A., Schneider L. S., Whitehouse P. J., Hoover T. M. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992 Oct 29;327(18):1253–1259. doi: 10.1056/NEJM199210293271801. [DOI] [PubMed] [Google Scholar]
  11. DeKosky Steven T., Ikonomovic Milos D., Styren Scot D., Beckett Laurel, Wisniewski Stephen, Bennett David A., Cochran Elizabeth J., Kordower Jeffrey H., Mufson Elliott J. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002 Feb;51(2):145–155. doi: 10.1002/ana.10069. [DOI] [PubMed] [Google Scholar]
  12. Erkinjuntti Timo, Kurz Alexander, Gauthier Serge, Bullock Roger, Lilienfeld Sean, Damaraju ChandrasekharRao Venkata. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002 Apr 13;359(9314):1283–1290. doi: 10.1016/S0140-6736(02)08267-3. [DOI] [PubMed] [Google Scholar]
  13. Farlow M. R., Hake A., Messina J., Hartman R., Veach J., Anand R. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001 Mar;58(3):417–422. doi: 10.1001/archneur.58.3.417. [DOI] [PubMed] [Google Scholar]
  14. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E., Donepezil MSAD Study Investigators Group A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001 Aug 28;57(4):613–620. doi: 10.1212/wnl.57.4.613. [DOI] [PubMed] [Google Scholar]
  15. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  16. Francis P. T., Palmer A. M., Snape M., Wilcock G. K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137–147. doi: 10.1136/jnnp.66.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Frisoni G. B. Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. J Neurol. 2001 Jul;248(7):551–557. doi: 10.1007/s004150170131. [DOI] [PubMed] [Google Scholar]
  18. Homma A., Takeda M., Imai Y., Udaka F., Hasegawa K., Kameyama M., Nishimura T. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord. 2000 Nov-Dec;11(6):299–313. doi: 10.1159/000017259. [DOI] [PubMed] [Google Scholar]
  19. Jacobs D., Sano M., Marder K., Bell K., Bylsma F., Lafleche G., Albert M., Brandt J., Stern Y. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994 Jul;44(7):1215–1220. doi: 10.1212/wnl.44.7.1215. [DOI] [PubMed] [Google Scholar]
  20. Joffres C., Graham J., Rockwood K. Qualitative analysis of the clinician interview-based impression of change (Plus): methodological issues and implications for clinical research. Int Psychogeriatr. 2000 Sep;12(3):403–413. doi: 10.1017/s1041610200006505. [DOI] [PubMed] [Google Scholar]
  21. Joffres Christine, Bucks Romola S., Haworth Judy, Wilcock Gordon K., Rockwood Kenneth. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. Dement Geriatr Cogn Disord. 2003;15(1):26–33. doi: 10.1159/000066673. [DOI] [PubMed] [Google Scholar]
  22. Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994 Apr 6;271(13):985–991. [PubMed] [Google Scholar]
  23. Knopman D. S., Knapp M. J., Gracon S. I., Davis C. S. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994 Dec;44(12):2315–2321. doi: 10.1212/wnl.44.12.2315. [DOI] [PubMed] [Google Scholar]
  24. Le Bars P. L., Katz M. M., Berman N., Itil T. M., Freedman A. M., Schatzberg A. F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA. 1997 Oct 22;278(16):1327–1332. doi: 10.1001/jama.278.16.1327. [DOI] [PubMed] [Google Scholar]
  25. Le Bars P. L., Kieser M., Itil K. Z. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. 2000 Jul-Aug;11(4):230–237. doi: 10.1159/000017242. [DOI] [PubMed] [Google Scholar]
  26. Licht Rasmus W. Limits of the applicability and generalizability of drug trials in mania. Bipolar Disord. 2002;4 (Suppl 1):66–68. doi: 10.1034/j.1399-5618.4.s1.27.x. [DOI] [PubMed] [Google Scholar]
  27. Livingston G., Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry. 2000 Mar;15(3):203–207. doi: 10.1002/(sici)1099-1166(200003)15:3<203::aid-gps100>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  28. Mayeux R., Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999 Nov 25;341(22):1670–1679. doi: 10.1056/NEJM199911253412207. [DOI] [PubMed] [Google Scholar]
  29. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano) 2001 Jun;13(3):143–162. doi: 10.1007/BF03351474. [DOI] [PubMed] [Google Scholar]
  30. McLendon B. M., Doraiswamy P. M. Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol. 1999 Spring;12(1):39–48. doi: 10.1177/089198879901200108. [DOI] [PubMed] [Google Scholar]
  31. Mitnitski A. B., Graham J. E., Mogilner A. J., Rockwood K. The rate of decline in function in Alzheimer's disease and other dementias. J Gerontol A Biol Sci Med Sci. 1999 Feb;54(2):M65–M69. doi: 10.1093/gerona/54.2.m65. [DOI] [PubMed] [Google Scholar]
  32. Mohs R. C., Doody R. S., Morris J. C., Ieni J. R., Rogers S. L., Perdomo C. A., Pratt R. D., "312" Study Group A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 Aug 14;57(3):481–488. doi: 10.1212/wnl.57.3.481. [DOI] [PubMed] [Google Scholar]
  33. Morris J. C., Cyrus P. A., Orazem J., Mas J., Bieber F., Ruzicka B. B., Gulanski B. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998 May;50(5):1222–1230. doi: 10.1212/wnl.50.5.1222. [DOI] [PubMed] [Google Scholar]
  34. Olin J., Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747–CD001747. doi: 10.1002/14651858.CD001747. [DOI] [PubMed] [Google Scholar]
  35. Oremus M., Wolfson C., Perrault A., Demers L., Momoli F., Moride Y. Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer's disease drug trials. Dement Geriatr Cogn Disord. 2001 May-Jun;12(3):232–236. doi: 10.1159/000051263. [DOI] [PubMed] [Google Scholar]
  36. Pryse-Phillips W. Do we have drugs for dementia? No. Arch Neurol. 1999 Jun;56(6):735–737. doi: 10.1001/archneur.56.6.735-a. [DOI] [PubMed] [Google Scholar]
  37. Qizilbash N., Whitehead A., Higgins J., Wilcock G., Schneider L., Farlow M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA. 1998 Nov 25;280(20):1777–1782. doi: 10.1001/jama.280.20.1777. [DOI] [PubMed] [Google Scholar]
  38. Quinn J., Moore M., Benson D. F., Clark C. M., Doody R., Jagust W., Knopman D., Kaye J. A. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002 Feb 12;58(3):433–437. doi: 10.1212/wnl.58.3.433. [DOI] [PubMed] [Google Scholar]
  39. Reisberg Barry, Doody Rachelle, Stöffler Albrecht, Schmitt Frederick, Ferris Steven, Möbius Hans Jörg, Memantine Study Group Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333–1341. doi: 10.1056/NEJMoa013128. [DOI] [PubMed] [Google Scholar]
  40. Rockwood K., Graham J. E., Fay S., ACADIE Investigators Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):500–507. doi: 10.1136/jnnp.73.5.500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rockwood K., MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001 May;20(2):51–56. doi: 10.1159/000054761. [DOI] [PubMed] [Google Scholar]
  42. Rockwood K., Mintzer J., Truyen L., Wessel T., Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589–595. doi: 10.1136/jnnp.71.5.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Rockwood K., Stolee P. Responsiveness of outcome measures used in an antidementia drug trial. Alzheimer Dis Assoc Disord. 2000 Jul-Sep;14(3):182–185. doi: 10.1097/00002093-200007000-00010. [DOI] [PubMed] [Google Scholar]
  44. Rockwood Kenneth, Joffres Christine, Halifax Consensus Conference on Understanding the Effects of Dementia Treatment Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations. Int J Geriatr Psychiatry. 2002 Nov;17(11):1006–1011. doi: 10.1002/gps.733. [DOI] [PubMed] [Google Scholar]
  45. Rockwood Kenneth, Wallack Michael, Tallis Raymond. The treatment of Alzheimer's disease: success short of cure. Lancet Neurol. 2003 Oct;2(10):630–633. doi: 10.1016/s1474-4422(03)00533-7. [DOI] [PubMed] [Google Scholar]
  46. Rogers S. L., Doody R. S., Mohs R. C., Friedhoff L. T. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998 May 11;158(9):1021–1031. doi: 10.1001/archinte.158.9.1021. [DOI] [PubMed] [Google Scholar]
  47. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., Friedhoff L. T. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998 Jan;50(1):136–145. doi: 10.1212/wnl.50.1.136. [DOI] [PubMed] [Google Scholar]
  48. Rogers S. L., Friedhoff L. T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia. 1996 Nov-Dec;7(6):293–303. doi: 10.1159/000106895. [DOI] [PubMed] [Google Scholar]
  49. Rosen W. G., Mohs R. C., Davis K. L. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356–1364. doi: 10.1176/ajp.141.11.1356. [DOI] [PubMed] [Google Scholar]
  50. Rösler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal-Bianco P., Stähelin H. B., Hartman R., Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633–638. doi: 10.1136/bmj.318.7184.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Schneider L. S., Olin J. T., Doody R. S., Clark C. M., Morris J. C., Reisberg B., Schmitt F. A., Grundman M., Thomas R. G., Ferris S. H. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 (Suppl 2):S22–S32. doi: 10.1097/00002093-199700112-00004. [DOI] [PubMed] [Google Scholar]
  52. Sokka Tuulikki, Pincus Theodore. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003 Feb;48(2):313–318. doi: 10.1002/art.10817. [DOI] [PubMed] [Google Scholar]
  53. Swanson G. Marie, Bailar John C., 3rd Selection and description of cancer clinical trials participants--science or happenstance? Cancer. 2002 Sep 1;95(5):950–959. doi: 10.1002/cncr.10785. [DOI] [PubMed] [Google Scholar]
  54. Tariot P. N., Solomon P. R., Morris J. C., Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000 Jun 27;54(12):2269–2276. doi: 10.1212/wnl.54.12.2269. [DOI] [PubMed] [Google Scholar]
  55. Thal L. J., Ferguson J. M., Mintzer J., Raskin A., Targum S. D. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12;52(6):1146–1152. doi: 10.1212/wnl.52.6.1146. [DOI] [PubMed] [Google Scholar]
  56. Thal L. J., Schwartz G., Sano M., Weiner M., Knopman D., Harrell L., Bodenheimer S., Rossor M., Philpot M., Schor J. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. Neurology. 1996 Dec;47(6):1389–1395. doi: 10.1212/wnl.47.6.1389. [DOI] [PubMed] [Google Scholar]
  57. Treves T. A., Verchovsky R., Klimovitsky S., Korczyn A. D. Recruitment rate to drug trials for dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):209–211. doi: 10.1097/00002093-200010000-00004. [DOI] [PubMed] [Google Scholar]
  58. Trinh Nhi-Ha, Hoblyn Jennifer, Mohanty Subhanjoy, Yaffe Kristine. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003 Jan 8;289(2):210–216. doi: 10.1001/jama.289.2.210. [DOI] [PubMed] [Google Scholar]
  59. Wilkinson D., Doody R., Helme R., Taubman K., Mintzer J., Kertesz A., Pratt R. D., Donepezil 308 Study Group Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26;61(4):479–486. doi: 10.1212/01.wnl.0000078943.50032.fc. [DOI] [PubMed] [Google Scholar]
  60. Wilkinson D., Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Sep;16(9):852–857. doi: 10.1002/gps.409. [DOI] [PubMed] [Google Scholar]
  61. Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A., Wetterholm A. L., Zhang R., Haglund A., Subbiah P. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489–495. doi: 10.1212/wnl.57.3.489. [DOI] [PubMed] [Google Scholar]
  62. van Dyck C. H., Newhouse P., Falk W. E., Mattes J. A. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. Arch Gen Psychiatry. 2000 Feb;57(2):157–164. doi: 10.1001/archpsyc.57.2.157. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Corrected Figure 1]
jnnpsyc_75_5_677__index.html (1.2KB, html)
jnnpsyc_75_5_677__1.pdf (57KB, pdf)

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES